PTC
VRTX icon

Private Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Private Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
548
+15
+3% +$6.65K 0.02% 699
2026
Q1 		$238K Sell
533
-7
-1% -$3.26K 0.02% 703
2025
Q4 		$245K Buy
540
+8
+2% +$3.45K 0.02% 684
2025
Q3 		$208K Sell
532
-454
-46% -$190K 0.02% 739
2025
Q2 		$439K Buy
986
+21
+2% +$9.68K 0.04% 449
2025
Q1 		$468K Buy
965
+7
+0.7% +$3.26K 0.05% 401
2024
Q4 		$386K Sell
958
-6
-0.6% -$2.78K 0.04% 477
2024
Q3 		$448K Sell
964
-191
-17% -$91.8K 0.05% 426
2024
Q2 		$541K Sell
1,155
-285
-20% -$124K 0.06% 350
2024
Q1 		$602K Buy
1,440
+104
+8% +$44K 0.07% 325
2023
Q4 		$544K Buy
1,336
+12
+0.9% +$4.43K 0.06% 323
2023
Q3 		$460K Buy
1,324
+2
+0.2% +$699 0.06% 334
2023
Q2 		$465K Buy
1,322
+212
+19% +$71.4K 0.06% 331
2023
Q1 		$350K Sell
1,110
-39
-3% -$11.7K 0.05% 391
2022
Q4 		$332K Buy
1,149
+279
+32% +$85K 0.05% 389
2022
Q3 		$252K Buy
870
+496
+133% +$143K 0.04% 428
2022
Q2 		$105K Buy
+374
New +$100K 0.02% 676
2014
Q4 		– Sell
-198
Closed -$22K – 1159
2014
Q3 		$22K Hold
198
– – 0.01% 819
2014
Q2 		$19K Buy
198
+14
+8% +$982 0.01% 852
2014
Q1 		$13K Hold
184
– – ﹤0.01% 878
2013
Q4 		$14K Sell
184
-234
-56% -$16.3K 0.01% 833
2013
Q3 		$32K Sell
418
-353
-46% -$28.1K 0.01% 533
2013
Q2 		$62K Buy
+771
New +$56.8K 0.03% 368

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Private Trust Company's VRTX Position: Q2 2026 in Review

Private Trust Company increased its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q2 2026, buying an estimated $6.65K and bringing the position to 548 shares worth $272K. The position accounts for 0.02% of the portfolio, ranked #699.

Private Trust Company first reported a position in VRTX in Q2 2013 and has held it in 23 quarters since. The position peaked at $602K in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Private Trust Company held 548 shares of Vertex Pharmaceuticals worth $272K as of Q2 2026.
  • Private Trust Company bought 15 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.65K.
  • Vertex Pharmaceuticals made up 0.02% of Private Trust Company's portfolio in Q2 2026, its #699 holding.
  • Private Trust Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 23 quarters since.
  • Private Trust Company's Vertex Pharmaceuticals position peaked at $602K in Q1 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.